SELLAS Life Sciences (SLS) Accumulated Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 12.06% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 12.06% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 35.51% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $3.5 million in the prior quarter.
• Over the last five years, Accumulated Expenses for SLS reached as high as $7.6 million in Q4 2023 and fell as low as $2.1 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $4.7 million across 5 years, with a median of $5.2 million in 2024.
• Across the five-year window, Accumulated Expenses surged 138.11% in 2022 and plunged 60.7% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $6.3 million in 2022, then gained by 21.7% to $7.6 million in 2023, then fell by 28.55% to $5.5 million in 2024, then plunged by 35.51% to $3.5 million in 2025, then slumped by 35.86% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.3 million in Q1 2026, $3.5 million in Q4 2025, and $3.0 million in Q3 2025.